We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Newly Developed Mobile Phone Device Reads ELISA Plates

By LabMedica International staff writers
Posted on 17 Aug 2015
A multidisciplinary team of scientists and clinicians have developed a handheld smartphone-based device that can quickly read standard 96-well microplates with the same level of accuracy as the platforms commonly used in central clinical laboratories. More...
The device, made by 3-D printing, attaches to the smartphone.

The research team from the University of California Los Angeles (UCLA; Los Angeles, CA, USA), led by Prof. Aydogan Ozcan along with Prof. Dino Di Carlo and Prof. Omai Garner, developed the ELISA reader to enable clinicians to perform these tests at lower cost and with greater flexibility for testing at point-of-care (POC), including in many resource-poor or field settings. “It is quite important to have these kinds of mobile devices, especially for administering medical tests that are usually done in a hospital or clinical laboratory,” said Prof. Ozcan, “This mobile platform can be used for point-of-care testing, screening populations for particular diseases, or tracking vaccination campaigns in most resource-poor settings.”

ELISA testing is most commonly performed with the standard 96-well transparent plastic plates that resemble honeycombs. The new device illuminates the plate with an array of light-emitting diodes (LEDs). The light projected through each well is collected by 96 individual plastic optical fibers. The smartphone transmits the resulting images to UCLA servers through a custom-designed app. The images are then analyzed by a machine-learning algorithm and the results are sent back to the phone for viewing within about 1 minute for the entire 96-well plate.

This mobile platform was compared with the standard FDA-approved well-plate readers at a UCLA clinical microbiology laboratory. The comparison included ELISA tests for mumps, measles, and herpes simplex viruses 1 and 2. Of a total of 571 patient samples, the mobile platform achieved 99.6% accuracy in diagnosing mumps, 98.6% for measles, and 99.4% each for herpes simplex 1 and 2.

“Our team is focused on developing biomedical technologies that work with mobile platforms to assist with on-site testing and health-care in disadvantaged or rural areas,” said Mr. Berg. Prof. Di Carlo added, “We are always looking toward the next innovation, and are looking to adapt the basic design of this ELISA cellphone reader to create smartphone-based quantified readers for other important medical tests.”

The work, by Berg B, et al, was reported online July 9, 2015, in the American Chemical Society journal ACS Nano.

Related Links:

UCLA
California NanoSystems Institute (at UCLA and UCSB)



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.